Gilead Balance Sheet Analysis From 2010 to 2024
GILD Stock | USD 66.76 0.60 0.91% |
Gilead |
Most indicators from Gilead Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Gilead Sciences Valuation and Gilead Sciences Correlation analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.31, whereas Issuance Of Capital Stock is forecasted to decline to about 295.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 27.3B | 27.3B | 27.1B | 28.5B | Interest Expense | 1.0B | 935M | 944M | 534.5M |
Gilead Sciences fundamental ratios Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Other Current Liab | 6.5B | 7.8B | 9.4B | 8.1B | 11.3B | 11.8B | |
Net Debt | 13.0B | 25.4B | 21.4B | 19.8B | 18.9B | 19.8B | |
Retained Earnings | 19.4B | 14.4B | 16.3B | 15.7B | 16.3B | 17.1B | |
Accounts Payable | 713M | 844M | 705M | 905M | 550M | 518.2M | |
Cash | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.8B | |
Other Current Assets | 1.4B | 2.0B | 2.1B | 1.8B | 2.4B | 1.3B | |
Total Liab | 39.0B | 50.2B | 46.9B | 42.0B | 39.4B | 41.3B | |
Total Current Assets | 31.5B | 15.8B | 15.1B | 15.2B | 16.5B | 10.8B | |
Short Term Debt | 2.5B | 2.8B | 1.5B | 2.3B | 1.8B | 1.9B | |
Net Receivables | 3.6B | 4.9B | 4.5B | 4.8B | 4.7B | 2.4B | |
Inventory | 2.1B | 3.0B | 2.7B | 2.8B | 3.4B | 3.5B | |
Other Liab | 6.5B | 9.5B | 35.3B | 7.3B | 8.4B | 8.8B | |
Other Assets | 3.1B | 4.8B | 6.0B | 1M | 1.2M | 1.1M | |
Long Term Debt | 22.1B | 28.6B | 25.2B | 23.0B | 23.2B | 12.2B | |
Net Tangible Assets | 4.6B | (23.0B) | (20.7B) | (16.0B) | (14.4B) | (13.7B) | |
Long Term Debt Total | 22.1B | 28.6B | 25.2B | 23.0B | 26.4B | 19.7B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Gilead Sciences Valuation and Gilead Sciences Correlation analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.